Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07543185

Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome

Sponsor: Shenyang Medical College

View on ClinicalTrials.gov

Summary

This study is a prospective, randomized, sham-controlled, participant- and assessor-blinded, parallel-group clinical trial designed to evaluate the clinical efficacy, mechanistic effects, and safety of right dorsolateral prefrontal cortex (DLPFC) closed-loop functional near-infrared spectroscopy brain-computer interface (fNIRS-BCI) neurofeedback in patients with high-ischaemic-risk chronic coronary syndrome (CCS) and comorbid anxiety disorder. Participants will be randomly assigned in a 1:1 ratio to active neurofeedback or sham feedback. The intervention consists of 4 weeks of treatment, with 20 sessions in total (1 session per weekday, approximately 20 minutes per session). The primary endpoint is the between-group difference in Hamilton Anxiety Rating Scale (HAMA) score at 3 months after treatment. Secondary endpoints include HAMA score and HAMA response rate at the end of treatment, as well as neurophysiological measures collected during Session 1, including right DLPFC activation, heart rate (HR), and heart rate variability (HRV). Exploratory long-term follow-up will assess cardiovascular and bleeding outcomes through 4 years after randomization.

Official title: Right Dorsolateral Prefrontal Cortex Closed-loop Neurofeedback for Anxiety in High-ischaemic-risk Chronic Coronary Syndrome: a Randomized, Sham-controlled Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

214

Start Date

2026-04-19

Completion Date

2031-02-20

Last Updated

2026-04-21

Healthy Volunteers

Conditions

Chronic Coronary Syndrome Anxiety Disorder High Ischemic Risk

Interventions

DEVICE

Active right DLPFC closed-loop fNIRS-BCI neurofeedback

A closed-loop functional near-infrared spectroscopy brain-computer interface (fNIRS-BCI) neurofeedback intervention targeting the right dorsolateral prefrontal cortex (DLPFC). Participants receive 20 sessions over 4 weeks, delivered once daily on weekdays, with each session lasting approximately 20 minutes. The training uses a 60-second cycle consisting of 20 seconds of rest and 40 seconds of auditory cueing, with a 1 Hz sinusoidally amplitude-modulated pure tone as the main cue. During training, the system provides real-time feedback coupled to right DLPFC hemodynamic activity to guide intentional downregulation.

DEVICE

Sham right DLPFC closed-loop fNIRS-BCI neurofeedback

A sham closed-loop functional near-infrared spectroscopy brain-computer interface (fNIRS-BCI) neurofeedback condition delivered with procedures identical to the active intervention, including the same visit schedule, auditory cues, training duration, interface appearance, and follow-up assessments. Participants receive 20 sessions over 4 weeks, delivered once daily on weekdays, with each session lasting approximately 20 minutes. The feedback signal is not meaningfully coupled to real-time right DLPFC activity.

Inclusion Criteria: * Participants will be aged 18 years or older and will provide written informed consent. * Participants will have chronic coronary syndrome (CCS) with prior coronary stent implantation more than 6 months before enrollment. * Participants will meet high ischemic risk (HIR) criteria by either of the following: * Percutaneous coronary intervention (PCI) performed more than 6 months earlier for acute coronary syndrome (ACS), including unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, with implantation of at least 1 coronary stent; or * PCI performed more than 6 months earlier for a non-ACS indication, together with at least 1 of the following risk factors: * diabetes mellitus; * diffuse multivessel coronary artery disease involving all 3 major coronary vessels; * chronic kidney disease with creatinine clearance less than 50 mL/min (recommended to be calculated using the Cockcroft-Gault formula); * prior stent thrombosis; * peripheral arterial disease; * complex PCI, defined by at least 1 of the following: * only patent remaining coronary vessel or left main coronary artery stenting; * implantation of at least 3 stents or treatment of at least 3 lesions; * bifurcation lesion treated with a 2-stent strategy; * total stent length greater than 60 mm; * PCI for chronic total occlusion. * Participants will meet DSM-5 diagnostic criteria for an anxiety disorder, confirmed by structured psychiatric interview. * Participants will have a Hamilton Anxiety Rating Scale (HAMA) score of 16 or higher. * Participants will have a 17-item Hamilton Depression Rating Scale (HAMD-17) score lower than 17. * Participants will not have used psychotropic medication, including antidepressants, anxiolytics, or antipsychotics, within 1 month before enrollment; prior psychotropic medication use will not itself exclude participation, provided that a washout period has been completed before enrollment and the medication history is documented. Exclusion Criteria: * Participants will be excluded if they have severe congestive heart failure (New York Heart Association class IV). * Participants will be excluded if they have moderate-to-severe valvular heart disease. * Participants will be excluded if they have a history of atrial fibrillation. * Participants will be excluded if they have unstable blood pressure, defined as systolic blood pressure greater than 180 mmHg or less than 90 mmHg. * Participants will be excluded if they are pregnant or breastfeeding. * Participants will be excluded if they have active or recent (within 6 months) severe systemic disease, including any of the following: * cerebrovascular disease, including stroke or transient ischemic attack; * dementia or severe cognitive impairment; * hyperthyroidism; * active pulmonary disease; * active malignant tumor. * Participants will be excluded if they have suicidal or homicidal risk based on clinical interview. * Participants will be excluded if they have other severe psychiatric disorders, including but not limited to: * psychotic disorders, such as hallucinations or delusions; * bipolar disorder.

Locations (1)

Second Affiliated Hospital of Shenyang Medical College

Shenyang, Liaoning, China